An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer

Giorgio V Scagliotti, Enriqueta Felip, Benjamin Besse, Joachim von Pawel, Anders Mellemgaard, Martin Reck, Lionel Bosquee, Christos Chouaid, Pilar Lianes-Barragán, Elaine M Paul, Rodrigo Ruiz-Soto, Entisar Sigal, Lone H Ottesen, Thierry Lechevalier

33 Citationer (Scopus)

Abstract

This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer.
OriginalsprogEngelsk
TidsskriftJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Vol/bind8
Udgave nummer12
Sider (fra-til)1529-37
Antal sider9
ISSN1556-0864
DOI
StatusUdgivet - dec. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater